DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. About Portage BiotechPortage Biotech is a clinical-stage im ...

DOVER, Del., June 09, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”) announce that on June 5, 2025 Portage and Compedica Holdings Limited, a company formed under the laws of the Isle of Man (“Compedica”) entered a mutual Subscription Agreement (“Subscription Agreement”). Pursuant to the Subscription Agreement, Portage issued 625,000 ordinary shares at a per share price of $8.00 in exchange ...

Group 1: Core Insights - Portage Biotech Inc. reports confirmatory preclinical efficacy data for PORT-7, a selective adenosine A2B receptor inhibitor, demonstrating superior single-agent activity compared to anti-PD1 antibody in a murine mesothelioma model [1] - The combination of PORT-7 and anti-PD1 showed enhanced efficacy over either agent alone, indicating a favorable immune response with increased immune effector cells and the formation of tertiary lymphoid structures [1] - Portage is preparing to initiate a first-in-human clinical trial for PORT-7, addressing the need for novel treatments in aggressive mesothelioma [1] Group 2: Ongoing Developments - Portage is advancing the dose escalation of PORT-6, a selective A2A adenosine receptor inhibitor, with plans to co-administer it with PORT-7 in the ADPORT-601 trial [2] - This combination aims to achieve complete blockade of adenosine-induced immunosuppression in the tumor microenvironment, enhancing anti-tumor responses and broadening the impact of immunotherapy in solid tumors [2] Group 3: Company Overview - Portage Biotech is a clinical-stage immuno-oncology company focused on advancing a pipeline of novel biologics to enhance the immune system's ability to combat cancer [3]

Portage Biotech Inc. PRTG on Thursday presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, at the 2025 European Lung Cancer Congress.The new data demonstrate both single-agent activity for PORT-7 and a dramatic >90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine mesothelioma animal model.Mesothelioma is a rare and aggressive cancer that develops in the thin tissue lining the lungs, abdomen, heart or testicles, strongly lin ...

Core Insights - Portage Biotech Inc. presented new preclinical data for PORT-7, a selective A2B receptor inhibitor, showing over 90% tumor growth inhibition when combined with an anti-PD-1 antibody in a murine mesothelioma model [1] - The company is preparing to initiate a first-in-human clinical trial for PORT-7, marking a significant step in addressing mesothelioma, an aggressive cancer with limited treatment options [1] - Portage is also advancing PORT-6, a selective A2A receptor inhibitor, with plans to co-administer it with PORT-7 in the ongoing ADPORT-601 trial to enhance immunotherapy effectiveness [2] Company Overview - Portage Biotech is a clinical-stage immuno-oncology company focused on developing novel biologics to enhance the immune system's ability to combat cancer [3]

Encouraging Safety Profile Supports Progression Toward First Dual-Administration of Selective A2A and A2B Antagonists in PatientsDOVER, Del., March 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the resumption of patient enrollment in the fourth and final cohort of the dose escalation stage for PORT-6, a highly selective A2A antagonist, within its ADPORT-601 P ...

Core Points - Portage Biotech, Inc. has received notification from Nasdaq that its compliance plan has been accepted, granting an extension to meet continued listing standards [1][2] - The minimum shareholders' equity required is $2.5 million, or alternatively, a market value of listed securities of at least $35 million or net income from continued operations of at least $500,000 in the most recent fiscal year or in two of the last three completed fiscal years [1] - Nasdaq will review Portage's adherence to the compliance plan periodically, with a deadline set for June 9, 2025, to regain compliance [2] Company Overview - Portage Biotech is a clinical-stage immuno-oncology company focused on developing novel biologics to enhance the immune system's ability to combat cancer [3]

DOVER, Del., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced that it has completed a private placement of $2.15 million from two Portage directors. The 524,390 ordinary shares were sold at $4.10 per share, the Nasdaq official Closing Price on January 22, 2025. Portage intends to use the proceeds from the financing for working capital and other general cor ...

Company Overview - Portage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of novel biologics to enhance the immune system's ability to fight cancer [4] - Cyncado Therapeutics is a wholly-owned subsidiary of Portage Biotech, focused on developing best-in-class small molecule adenosine receptor antagonists targeting A2a and A2b receptors for oncology indications [5] Strategic Development - Portage Biotech re-launched its wholly-owned subsidiary as an independently managed company named Cyncado Therapeutics, with Peter Molloy appointed as CEO [1] - The re-launch aims to unlock the full potential of Portage's adenosine program and maximize value for shareholders [3] Therapeutic Focus - Cyncado Therapeutics is advancing A2a and A2b receptor antagonists, which are designed for dual administration to maximize synergy and achieve a comprehensive blockade of immune evasion pathways [2][5] - These therapeutics aim to enhance the immune system's ability to mount a robust anti-tumor response, potentially transforming immuno-oncology [2] Leadership and Vision - Peter Molloy, CEO of Cyncado Therapeutics, expressed confidence in the potential of adenosine pathway therapeutics and committed to advancing clinical programs toward proof of concept [3] - Alex Pickett, CEO of Portage Biotech, emphasized the strategic importance of the re-launch and Peter Molloy's expertise in accelerating clinical progress [3] Clinical and Financial Goals - Cyncado Therapeutics is focused on securing external financing and advancing clinical development to achieve proof-of-concept data for its therapeutics [2][3] - The company aims to establish its therapeutics as transformative treatments in oncology [3]

WESTPORT, Conn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, is pleased to announce that it has entered into a Letter of Intent ("LOI") with Immunova, LLC, ("Immunova") a private Connecticut-based biotechnology company. Under the terms of the LOI, Portage and Immunova have agreed to negotiate a definitive option agreeme ...